Author

Chloe A Paolucci

Columbia University Irving Medical CenterORCID 0000-0002-6979-2929Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Albert HungiD· 1 shared Alison Marie TayloriD· 1 shared Anjali SaqiiD· 1 shared Brian S. HenickiD· 1 shared David A. BakeriD· 1 shared Denys OliinykiD· 1 shared Domenico AcciliiD· 1 shared Elisabeth Zollbrecht· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Albert HungORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Aneuploidy sensitizes cells to SREBP-pathway inhibition in squamous cell carcinoma

Nadja Zhakula-Kostadinova, Sejal Jain, Zeinab Amini‐Farsani, Jiankang Zhang, Mari Nakamura, Laura Byron, Joan Josep Castellano, Chloe A Paolucci, Rohan Munoth, Fereshteh Zandkarimi, Yuka Takemon, Marco A. Marra, Brian S. Henick, Anjali Saqi, Tannishtha Reya, , Alison Marie Taylor

This study identifies that 3q-gain aneuploidy in squamous cell carcinomas creates a vulnerability to SREBP-pathway inhibition, offering a target for lipid-targeted therapies.

bioRxiv · May 8, 2026 · PreprintCancer Biology

Reprogramming insulin receptor activation with a de novo agonist to overcome severe insulin resistance

Albert Hung, Xinru Wang, Michael Gao, Michelle Ng, Denys Oliinyk, Riley R. Weaver, Elisabeth Zollbrecht, Sarah Caixeta Cardoso, Gregory Sebastien Ronel, Chloe A Paolucci, Jianxiang Ye, Qing Fan, Elizabeth M. Rhea, Matthias Mann, David A. Baker, , Eunhee Choi

This study develops a de novo insulin receptor agonist, RF-409, which effectively treats severe insulin resistance in a mouse model by activating a mutant receptor and improving glucose homeostasis.

bioRxiv · May 7, 2026 · PreprintPharmacology & Toxicology